Schatlo, BawarjanHenning, Erica C.Pluta, Ryszard M.Latour, Lawrence L.Golpayegani, NahalMerrill, Marsha J.Lewin, NaomiChen, YongOldfield, Edward H.2022-08-232022-08-232007-08-092008-09-22J Cereb Blood Flow Metab. 2008 Mar;28(3):482-9. Epub 2007 Aug 8. <a href="http://dx.doi.org/10.1038/sj.jcbfm.9600542">Link to article on publisher's site</a>0271-678X (Print)10.1038/sj.jcbfm.960054217684515https://hdl.handle.net/20.500.14038/33783An adjuvant therapy to prolong the therapeutic window for stroke patients is urgently needed. This randomized, blinded, placebo-controlled study investigated adjuvant intravenous sodium nitrite with recombinant tissue plasminogen activator (rtPA) in middle cerebral artery occlusion (MCAO) with 6 and 2 h of ischemia followed by reperfusion in Sprague-Dawley rats (n=59). Quantitative diffusion, T(1)-, T(2)-weighted, and semiquantitative perfusion imaging were performed before and after reperfusion and at 48 h after ischemia to determine the spatiotemporal evolution of stroke. After 48 h animals were killed and examined to evaluate infarct size and evidence of hemorrhagic transformation. Factor VIII immunostaining was performed to assess vessel morphology. Nitrite treatment (6 h group: 37.5 micromol for more than 90 mins; 2 h group: 26.25 and 1.75 micromol for more than 60 mins) did not reduce infarct volume 48 h after MCAO compared with saline-treated placebo groups after 6 or 2 h of MCAO. Stroke progression from baseline to 48 h, based on the apparent diffusion coefficient and relative cerebral blood flow deficits before and after reperfusion and T(2)-weighted hyperintensity at 48 h, did not differ between treated and control animals. These results suggest that nitrite is not a protective adjuvant therapy to delayed rtPA administration after ischemic stroke in rats.en-USJournal Articlehttps://escholarship.umassmed.edu/gsbs_sp/444635319gsbs_sp/444